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ABSTRACT

There are extremely important uses for platinum when it comes to the treatment
of cancers and dementias. One potential therapeutic combines platinum with a structure
known as phenanthroline. This platinum phenanthroline structure is normally extremely
water-insoluble, rendering it difficult to study and use in biological systems. The
Williams’ Biochemistry Laboratory endeavored to find a simpler synthetic pathway for a
water-soluble phenanthroline product. While unsuccessful in identifying a product as of
yet, many synthetic pathways have been ruled out, and more hypothetical pathways are
being formulated for testing.
Among the strategies analyzed are varying solvent, reagents, apparatus,
methodology, and temperature in order to coax platinum(II) 1,10-phenanthroline
dichloride into solution to promote reaction with more water-soluble compounds. Among
potential future hypotheses are the use of harsher solvents and potentially increasing the
oxidation state of platinum.
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INTRODUCTION

Introduction to Platinum Compounds
Platinum-based compounds have been used in the treatment of disease and
advancement of science since the mid-eighteenth century. One of the important chemical
properties of platinum is its ability to coordinate multiple covalent bonds. Platinum (II)
can coordinate up to four covalent bonds, whereas the more oxidized version, platinum
(IV), can maintain six stable bonds, as seen in satraplatin (Johnstone, Park, & Lippard
2014).
While there are a multitude of compounds containing platinum used in medicine,
many unsuccessful candidates struggle with providing adequate bioavailability. Since
platinum is a stable heavy metal that coordinates with DNA, it provides considerable
cytotoxicity in biologically active systems. Medicinal compounds containing platinum
include drugs used in the treatment of cancers such as cisplatin and oxaliplatin. One of
the first functions of these drugs was to act as an antineoplastic, preventing or reversing
the onset of paraneoplastic syndrome in cancer patients (Johnstone, Park, & Lippard,
2014).
There are other forms of platinum compounds commonly used in scientific study.
Platinum compounds frequently used in laboratory settings include tetrachloroplatinate,
elemental platinum (II) and platinum (IV), and various catalytic salts. Platinum’s modern
primary use is as a catalyst for a variety of chemical reactions.
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History and Synthesis of Phenanthroline
One family of platinum compounds – those containing or derived from a 1,10phenanthroline ligand – have been detailed in the scientific literature since Monatsh
Blau’s discovery in 1898.
Figure 1

[Chemical Structure of Platinum (II) 1,10-Phenanthroline]

A refined synthetic method for synthesis of o-phenanthroline was published by
Breckenridge and Singer (1947). The synthetic process outlined in the mid 20th century
dictates the use of two successive Skraup reactions to synthesize o-phenanthroline from
glycerol and o-phenylenediamine (Halcrow & Kermack, 1946).
The general mechanism for a Skraup synthesis is shown below in Figure 2:
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Figure 2

[image sourced from Wikipedia article on Skraup reactions. Z.H. Skraup published the
general model for quinoline synthesis in 1880 manuscript “Eine Synthese des Chinolins.”
Note that this model is archetypal and is not the Skraup reaction for phenanthroline.]
At the conclusion of the Skraup reaction, the o-phenanthroline compound can be reacted
in hydrochloric acid solution under a nitrogen gas atmosphere with tetrachloroplatinate to
3

form Platinum (II) 1,10-phenanthroline dichloride (IUPAC preferred name:
dichloroplatinum;1,10-phenanthroline) [Pt(II)(phen)](Sun, et al. 2019).
Properties of Phenanthroline Compounds
At the conclusion of a Skraup reaction an aromatic multi-ring structure is formed.
In the instance of (phen), there are nitrogen atoms at the 1 and 10 positions of the ring
structure. Phenanthroline derived compounds exhibit varying levels of pKa, solubility,
and bioactivity. Of particular concern is Pt(II)(phen)Cl 2. There is very limited data
available on the compound. Figure 3 Shows the complex which phenanthroline creates
with platinum.
Figure 3

[dichloroplatinum;1,10-phenanthroline]

Platinum can then form two other coordinate covalent bonds, either with a bidentate
ligand, or with two separate atoms or molecules.
Phenanthroline’s appearance on 1H nuclear magnetic resonance spectroscopy
[NMR] shows 4 groups of peaks. Figure 4 shows standard (phen) spectra (with and
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without a platinum complex), along with a labeled diagram assigning each proton to a
peak.
Figure 4

[Standard 1,10-Phenanthroline Peak assignments. Adapted from Sun, et al. 2019.]

Due to the symmetry of the molecule along the central line of the platinum, there are only
four expected peak groups associated with 1,10-phenanthroline. 1H-NMR assists with
identification of the compounds synthesized or utilized in experiments.
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Solubility and Bioavailability
The platinum coordinated (phen) compound discussed above has no known
remarkable solubility in water. Limited efforts have been documented in synthesizing
derivative compounds which both include Pt(II)(phen) and also increase the water
solubility of the compound. Of particular note are alkoxyacetate compounds synthesized
by Sun, et al. (2019), which show considerably increased bioavailability and cytotoxicity
when uptake occurs in various tumor cell lines. Their study showed a maximum
solubility of 17.5 mg/ml when the coordinated ligand for platinum was alkoxyacetate.
While these particular compounds have not been reproduced, it shows important promise
for the phenanthroline ligand.
In a review of current literature, no published data has been found for in vitro
bioavailability of Pt(II)(phen) in mammalian subjects. It is suspected, however, that due
to the extreme insolubility of the species, bioavailability would approach zero percent.
Current Research into Phenanthroline
A few studies of note demonstrate the potential of o-phenanthroline. Halcrow and
Kermack (1946) attempted to derive new antimalarial compounds based on
phenanthroline from quinolines. The study demonstrated that the aromatic rings
themselves could have substituents added using simple organic chemistry methods.
However, these o-phenanthroline compounds are distinct from their platinum-coordinated
derivatives described earlier. While likewise having low solubility in water, they do not
share the same level of cytotoxicity and chelating ability as the Pt(II)(phen) compounds.
Barnham, et al (2008) described how Pt(II)(phen)Cl 2 could potentially be used to
prevent aggregation of β-amyloid [Aβ] into insoluble plaques. By binding to histidine

6

residues in Aβ, Pt(II)(phen) can inhibit essential metal activity and reduce toxicity that
the plaques cause in synapses. The Pt(II)(phen)Cl 2 lowers oxidative stress by inhibiting
formation of Aβ-Copper(II) complexes which are known to catalyze formation of
peroxides [Opazo, et al. 2002]. The (phen) ligand shows higher affinity for Aβ than other
neurological proteins in situ.
Sun, et al. (2019) utilized structurally similar derivatives of Pt(II)(phen) in order
to increase solubility of the phenanthroline. They showed that some of these compounds
were cytotoxic and readily taken in by tumor cell lines in culture, yet less potent than the
traditional anticancer platinum drugs.
There has been a reasonable amount of data published which demonstrates
Pt(II)(phen) based compounds as potential targeted therapeutics for complex medical
ailments such as cancers and Alzheimer’s disease. However, the extreme insolubility of
stock compounds creates a severe inability to utilize findings presented in the literature
for the advancement of therapeutics. By understanding the implications of a relatively
easily synthesized yet soluble compound, one can easily understand the need to develop
and properly characterize such a compound. Various methods have been employed to
attempt this feat, and to analyze and characterize any resulting compound which may be
created.

7

EXPERIMENTAL

General Considerations
Among much of the general operating theory of this project in the Williams’
Biochemistry Laboratory is that if Pt(II)(phen)Cl2 can undergo a displacement reaction
with silver oxalate [Ag2(ox), ox = C2O4-2] to create Pt(II)(phen)(ox) and a silver chloride
precipitate, the oxalate product would likely be appropriately water-soluble. The most
difficult task has been identifying an appropriate anhydrous solvent which can pull the
Pt(II)(phen) compound into solution without creating solvation products or creating an
environment too harsh to isolate the desired product.
In order to identify an appropriate solvent, a qualitative solubility survey was
conducted. A few milligrams of commercially available Pt(II)(phen)Cl 2 were dissolved in
four milliliters each of deionized (DI) water, acetone, chloroform, dichloromethane
(DCM), and methanol. After 24 hours of stirring in microvials, the DCM and acetonitrile
appeared to best pull the phenanthroline compound into solution. However, after another
48 hours without stirring, all compounds appeared to settle back as precipitates. While
none of these compounds were analyzed using spectroscopic methods to verify that the
compound had failed to go into solution, this qualitative study demonstrated the difficulty
which would be present throughout all experiments conducted.
As a precursor to discussing individual experiments, Table 1 below shows each
reagent, solvent, and notes of the reaction sequence which have been attempted for
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Pt(II)(phen). Table 2 shows each reagent, solvent, and notes of the reaction sequence
which have been attempted for platinum (II) neocuproine dichloride [Pt(II)(neo)], which
is sterically and chemically similar to 1,10-phenanthroline. Each experiment will be
discussed in depth.

Table 1: Summary of Platinum (II) 1,10-Phenanthroline Dichloride Reactions
Reagent
Solvent
Notes
Silver Oxalate
DI Water
Yellow resulting solution.
Light orange precipitate
after drying.
Histidine
DMSO-d6/D2O
Quick exergonic reaction.
N-Acetyl-L-Methionine
DMSO-d6/D2O
Silver Oxalate
DMF
Green-yellow solution.
NMR characterized using
both D2O and DMSO-d6.
Silver Oxalate
DCM
Concentrated under
vacuum. Crystals knocked
out with diethyl ether.
Silver Nitrate
DCM
Concentrated under
vacuum. Crystals knocked
out with diethyl ether.
Table 2: Summary of Platinum (II) Neocuproine Dichloride Reactions
Reagent
Solvent
Notes
Histidine
DMSO-d6/D2O
Exergonic reaction.
N-Acetyl-L-Methionine
DMSO-d6/D2O
Neocuproine compound
reluctant to enter solution.
Silver Oxalate
DMSO
Unremarkable.
Silver Oxalate
DI Water
Unremarkable.

Stock Synthesis Reactions
Two compounds utilized throughout multiple experiments were synthesized in
house. The synthetic strategy of Ag2(ox) and Pt(II)(neo)Cl2 are explained below.
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Silver Oxalate: Although stock bottles of the reagent are available for purchase, it was
more cost effective to synthesize the compound as needed in the lab. To synthesize
Ag2(ox), 250 mg of silver nitrate was combined with 125 mg of anhydrous oxalic acid
with 50 mL of DI water in an amber bottle. The solution was stirred overnight, and
vacuum filtered. The final product was a white, powdery precipitate. The product was
stored in an Eppendorf tubule in complete darkness to prevent unwanted photoreactions.
Platinum (II) Neocuproine Dichloride: The synthesis of the (neo) compound consisted
of two consecutive reactions. First, 1.25 g of potassium tetrachloroplatinate were
dissolved in 10 mL of DI water. Once dissolved, 639 mL of DMSO was added. After
stirring for just under a day, yellow crystals were observed, and the original red color of
the tetrachloroplatinate was no longer present. This yellow precipitate was gravity filtered
and dried overnight. This resulting compound, not characterized by NMR, is believed to
be Pt(II)(DMSO)Cl2.
The DMSO compound was used to synthesize the (neo) compound. First, 315 mg
of the DMSO compound and 156 mg of pure (neo) were brought into solution using 80
mL of ethanol. This solution was refluxed for one day. After reflux, the resulting solution
was rotary evaporated, and the resulting solid was dissolved in dichloromethane. This
new solution was then run through a silica gel column, and a yellow solution was
collected and dried. This final compound is characterized as Pt(II)(neo)Cl 2.
Silver Oxalate Reactions
There are four reactions which utilized silver oxalate as a reagent: three (phen)
and one (neo). No reactions produced confirmed water-soluble products, but one
produced a potential success which could not be confirmed by NMR.
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In the first two phenanthroline reactions, one used DI water as the solvent, and the
other used N,N-dimethyl formamide (DMF). The DI water reaction was allowed to stir
overnight in an amber bottle, and then was gravity filtered, and the resulting solution was
rotary evaporated. This produced the expected failed reaction, although a minor color
change in the precipitate from light yellow to light orange was recorded. NMR data did
not show evidence of any of the expected compounds (reactants or products), and
therefore the reaction was considered unsuccessful.
The reaction utilizing DMF, Ag2(ox), and (phen) marked the strongest anhydrous
solvent used as of yet. A sickly green-yellow color precipitate was formed after the
solution was allowed to stir overnight. The resultant compound was characterized by
NMR in both dimethyl sulfoxide-d6 (DMSO-d6) and deuterium oxide (D2O).

Dichloro Platinum (II) 1,10-Phenanthroline + Oxalic Acid + DMF in D2O
(File: JMY_PtPhen_Oxal_DMF_D2O_Wk_1)

abundance
-0.02-0.01 0
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Figure 5: 1H NMR of Silver Oxalate and Platinum (II) 1,10-Phenanthroline in D 2O
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[This spectra shows the result of reaction between silver oxalate and platinum(II) 1,10phenanthroline with DMF as the solvent. Product dissolved in D 2O.]
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The NMR data presented shows a variety of peaks set between 2.6-3.1 ppm. These shifts
are not expected in phenanthroline compounds. Since silver oxalate does not contain any
additional deuterated protons, it is unclear what compound is present, and whether it has
any significance in the data.

Figure 6: 1H NMR of Silver Oxalate and Platinum (II) 1,10-Phenanthroline in

Dichloro Platinum (II) 1,10-Phenanthroline + Oxalic Acid + DMF in DMSO, 8.0-10.0 ppm [part 1]
(File: JMY_PtPhen_Oxal_DMF_DMSO)
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[This spectra shows the upfield shifts in the reaction between silver oxalate and
platinum(II) 1,10-phenanthroline with DMF as the solvent. Product dissolved in DMSO.]

The data depicted shows peaks consistent with (phen) shielded by the addition of more
electronegative atoms, such as oxygen on the (ox). All of the peaks exist in the 8.0-10.0
ppm range in the NMR, suggesting aromaticity.
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Figure 7: 1H NMR of Silver Oxalate and Platinum (II) 1,10-Phenanthroline in
DMSO (0.7-3.0 ppm)
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Dichloro Platinum (II) 1,10-Phenanthroline + Oxalic Acid + DMF in DMSO, 0.7-3.0 ppm [part 2]
(File: JMY_PtPhen_Oxal_DMF_DMSO)
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[This spectra shows the downfield shift in the reaction between silver oxalate and
platinum(II) 1,10-phenanthroline with DMF as the solvent. Product dissolved in DMSO.]

The NMR data presented shows a variety of peaks set between 0.7-3.0 ppm. These shifts
are not expected in (phen) compounds. Since Ag2(ox) does not contain any additional
deuterated protons, it is unclear what compound is present, and whether it has any
significance in the data. The large peaks at 1.2 ppm and 2.5 ppm may be a residual
solvent such as acetone or water.
The final unsuccessful trials with silver oxalate were with (neo) rather than
(phen). This reaction in both DI water and DMSO (following the same procedure as for
phenanthroline) yielded no considerable products, and no identifiable products could be
identified on NMR.
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There was one trial with Ag2(ox) and (phen) which has yielded inconclusive
results, yet the most likely result is the lack of meaningful reaction. In this reaction, the
reagents were allowed to stir overnight in dichloromethane. The resulting solution was
concentrated from 50 mL to 15 mL by rotary vacuum. Then, 5 mL of diethyl ether was
added, and a sandy yellow precipitate was drawn out of solution. This precipitate was
gravity filtered, dried overnight, and analyzed via NMR using D 2O. The NMR data
showed no indications of any compounds present in solution and is not included due to its
lack of remarkability. However, it was observed that the physical characteristics of the
resultant compound were noticeably different to the original phenanthroline, and the
compound appeared to go into solution under vortex but would quickly settle when
unagitated.
Silver Nitrate Reactions
There were a few reactions conducted with silver nitrate, each involving (phen).
Of particular note was a reaction scheme which paralleled the (phen), (ox), and DCM
pathway. The method followed for each was identical, with the only alteration being the
use of silver nitrate instead of silver oxalate. The NMR data once more lacked any
significant signals. The observation of the resultant compound in preparation for NMR
showed the yellow product being pulled into solution, and the entire solution becoming
colorless. It is not confirmed if this product was the intended one, but it is reasonable to
conclude that not enough product was drawn fully into solution to yield significant
results.
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Amino Acid Reactions
A few non-synthetic reactions were conducted to examine the interactions of the
phenanthroline and neocuproine compounds with methionine [Met] and N-acetyl-Lhistidine [His]. These reactions are important in confirming whether the (neo) and (phen)
ligands have potential to be biologically active. All four series of reactions were
conducted in microscale in 80:20 DMSO-d6/D2O. All four produced heat at the addition
of D2O, as the process of bringing amino acids into solution is an exergonic process. The
NMR data of all four reactions was collected at multiple time points for comparison and
compared with the NMR spectra of the stock compounds; at all readings, the instrument
was calibrated for the DMSO-d6 signal.

Figure 8: 1H NMR for Platinum (II) 1,10-Phenanthroline Dichloride and LHistidine in 50:50 DMSO-d6/D2O
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Dichloro Platinum (II) 1,10-Phenanthroline + L-Histidine in 50:50 DMSO/D2O
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[The above spectra shows the spectra collected at three different time points for a
reaction between Pt(II)(phen)Cl2 and (His).]
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Figure 9: 1H NMR for Platinum (II) 1,10-Phenanthroline Dichloride and N-AcetylL-Methionine in 50:50 DMSO-d6/D2O
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Dichloro Platinum (II) 1,10-Phenanthroline + N-Acetyl-L-Methionine in 50:50 DMSO/D2O
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[The above spectra shows the spectra collected at three different time points for a
reaction between Pt(II)(phen)Cl2 and (Met).]

Both of the above spectra demonstrate a general shift in chemical pattern over time in
sealed systems. This suggests that there is a product after three and seven days which was
not present initially. Most importantly, this NMR data suggests that the (phen) compound
is bioactive with histidine and methionine, as suggested by Barnham et al. (2008).
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DISCUSSION

Discussion of Results
One may analyze the results and forget to consider the implications of nonaffirmative results. Of note, there are multiple synthetic pathways that have been ruled
out as feasible in creation of a viable water-soluble (phen) or (neo) compound. From
these unsuccessful syntheses, one can extrapolate other potential non-starting points,
better streamlining the research into synthesis of a final, usable compound. For instance,
since the qualitative solubility study mentioned earlier yielded similar results for all six
solvents utilized (DI water, acetonitrile, acetone, chloroform, dichloromethane,
methanol), it can be reasonable assumed (although not empirically ruled out) that the
unused solvents would produce similar reactions, or lack thereof.
Experiments conducted also verify the potential bioactivity of (phen) and (neo),
exhibited by the reactions with (His) and (Met). This confirmed reactivity further
emphasizes the need for research into water-soluble and bioavailable compounds. If these
compounds can be synthesized, then studies can be undertaken which utilize living
biological models, such as mice and potentially humans.
Hypothetical Approaches for Future Work
There are a few theoretical approaches which can be considered as potential
synthetic pathways for future research. Of these, there are two primary concepts two
examine: using a wider variety of solvents and increasing the oxidation state of the
platinum.
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Change the Solvent: There are a variety of harsher solvents and processes which can be
utilized to force the highly insoluble (phen) into solution. Among these strategies include
the use of polar aprotic solvents which better facilitate the creation of polar compounds.
Since water best dissolves polar compounds, polar aprotic solvents like DMF, DMSO,
and tetrahydrofuran (THF) can help facilitate creation or preservation of net-dipole
moments in newly synthesized compounds, producing net polarity. Some of these
solvents may contain residual water, which can be pulled out of the solution using
molecular sieves.
Some of these stronger solvents may require the use of different methods to
isolate a product than simple filtration or evaporation. Many of these methods are still
relatively basic isolation techniques, such as extraction using immiscible aqueous and
organic phase solvents. Alternatively, if the product remains in solution and is not
precipitated out, it might be possible to produce hydrochloride salts by adding
hydrochloric acid and ether.
Oxidize the Platinum: Perhaps one of the more novel methods is to alter the oxidation
state of the platinum from platinum(II) to platinum(IV). This strategy is derived from the
synthetic method used in the creation of satraplatin. Platinum (IV) octahedral compounds
are kinetically inert and act as prodrugs rather than directly as bioactive compounds.
According to Karmakar et al. (2019), the synthesis of a six-coordinate platinum(IV)
complex arises from oxidative addition of ligands. Oxidative addition of platinum from
4-coordination to 5-or-6-coordination has its most difficult step in the activation of the
platinum(II) into accepting more covalent bonds (Rendina & Puddephatt, 1997). Once
activated, the platinum can relatively readily accept extra ligands through S N2, concerted,
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and homolytic bond addition mechanisms. A potential product of a successful reaction of
this form may appear as Figure 10:
Figure 10

[dichlorooxaloplatinum; 1,10-phenanthroline]

To lower potential cytotoxicity and to increase the molecules bioactivity, the two
chloride ions would be cleaved from the molecule, leaving just the (phen)(ox) ligand to
act on the proteins. This would result in the original desired product through an indirect
synthetic pathway which takes advantage of platinum’s multivalent capabilities. It is
anticipated that polarity of the overall compound would be considerable enough to
dissolve in water.
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CONCLUSION

Platinum and phenanthroline related research has been a promising area of
medical science for over fifty years. Among the common pitfalls of the research into
these areas is the lack of solubility and bioavailability of the readily synthesized
compounds, leaving much of the research findings inapplicable to humans for the time
being. The research of the Williams’ Biochemistry Laboratory attempted to remedy some
of these pitfalls and create compounds which could be utilized in living biological
systems to further research applications. While a compound has not at this point been
synthesized, it is reasonably believed that there are compounds which can be created, and
multiple potential methods have been identified, ruled out, or hypothesized. Platinum (II)
1,10-phenanthroline remains a stubborn yet promising compound.
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